|
Report Date : |
30.04.2012 |
IDENTIFICATION DETAILS
|
Name : |
SAM-A PHARM. CO., LTD |
|
|
|
|
Registered Office : |
1676, Donghwa-ri, Munmak-eup, Wonju-si, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
04.10.1973 |
|
|
|
|
Com. Reg. No.: |
138-81-05823 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Finished Medicaments |
|
|
|
|
No. of Employees : |
290 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
Usually Correct |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com while quoting report
number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
|
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Company Name |
SAM-A PHARM. CO., LTD. |
|
Registered Address |
1676, Donghwa-ri, Munmak-eup, Wonju-si, |
|
Building |
|
|
Zip Code |
220-801 |
|
Tel |
+82-33-769-8400 |
|
Fax |
+82-33-769-8403 |
|
E-mail |
kimth@samapharm.co.kr |
|
Website |
www.samapharm.co.kr |
|
Trading Address |
Sama Bldg., 80-18, Cheongdam-dong, Gangnam-gu, |
|
Tel |
+82-2-2056-7200 |
|
Fax |
+82-2-2056-7300 |
|
Other Address |
486, Sin-dong, Yeongtong-gu, Suwon-si, |
|
Tel |
+82-31-695-8265 |
|
Fax |
|
|
Other Address |
Rm.612, 174, Ojeon-dong, Uiwang-si, |
|
Tel |
+82-31-445-0310 |
|
Fax |
+82-31-427-0310 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Finished Medicaments |
|
Main Business |
|
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
10/04/1973 |
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Cough and cold and antiallergy products(51161800) |
|
Sell |
Non narcotic analgesics and antipyretics(51142000) |
|
Sell |
Dietary supplements and nutritional therapy products(51191900) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Sell |
Cardiovascular drugs(51120000) |
|
Buy |
Formulas and products for nutritional support(42231800) |
|
Buy |
Chemistry reagents or solutions(41116105) |
|
Buy |
Ascorbic acid(12162201) |
|
Buy |
Biochemicals(12352200) |
|
Buy |
Organic acids or its substitutes(12352106) |
|
Buy |
Chemicals including Bio Chemicals and Gas Materials(12000000) |
|
Buy |
Acetaminophen(51142001) |
|
Buy |
Dexchlorpheniramine maleate(51161603) |
|
Name |
Heo Jun |
|
Address |
|
|
Date of Birth |
06/25/1971 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital |
6,370,000,000 KRW |
||||||||||||||||||||||||
|
Employees |
290 |
||||||||||||||||||||||||
|
Formation |
Listed Company (KOSDAQ : 009300) as of 07/19/2000 |
||||||||||||||||||||||||
|
Bank Details |
Hana Bank |
||||||||||||||||||||||||
|
Corporate Registered No. |
134111-0000765 |
||||||||||||||||||||||||
|
Business Registered No. |
138-81-05823 |
||||||||||||||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 11167866 |
||||||||||||||||||||||||
|
Shareholder Position |
|
||||||||||||||||||||||||
|
Company History |
10/04/1973 Incorporated as Sam-A Pharm
Industries Co., Ltd. 03/2007 Changed company name to the present
name 01/2010 Moved to the present HQ address |
||||||||||||||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
Chairman & CEO |
Mr. |
Heo Jun |
Korean |
1971.06.25 |
The University of |
|
Director |
M/S. |
Heo Mi-Ae |
Korean |
1975.03.14 |
|
|
Outside Director |
Mr. |
Choi Young-Kwang |
Korean |
1940.11.03 |
|
|
Auditor |
Mr. |
Park Don |
Korean |
1955.02.20 |
|
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
56,857,631,006 |
137,864,942,750 |
9,822,027,169 |
|
|
(*)2010 |
54,737,275,045 |
128,751,327,286 |
23,004,104,277 |
|
2009 |
53,093,603,005 |
111,100,902,479 |
3,505,698,752 |
|
2008 |
44,629,977,492 |
96,274,779,649 |
4,209,188,441 |
|
2007 |
40,638,184,026 |
85,037,636,338 |
3,762,927,081 |
|
2006 |
40,292,615,236 |
82,184,746,774 |
4,652,257,325 |
|
2005 |
39,366,127,484 |
77,889,499,902 |
6,185,911,551 |
(*)2010 and
2011 ‘s figures are based on the K-IFRS Accounting System.
Financial Description
|
Authorized Capital(KRW) |
15,000,000,000 |
|
Paid-Up Capital(KRW) |
6,370,000,000 |
|
Total Issues Shares |
6,370,000 |
Balance
Sheet
|
|||
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Total Assets |
137,864,942,750 |
128,751,327,286 |
|
|
Current Assets |
62,317,879,009 |
52,899,547,283 |
|
|
Cash & Cash Equivalents |
8,235,828,665 |
16,012,667,983 |
|
|
Trade Receivables & Other
Receivables |
20,305,187,104 |
19,398,373,891 |
|
|
Current Financial Instruments |
22,003,480,023 |
6,792,450,919 |
|
|
Inventories |
10,271,384,647 |
10,251,148,357 |
|
|
Other Current Assets |
1,501,998,570 |
444,906,133 |
|
|
Non-Current Assets |
75,547,063,741 |
75,851,780,003 |
|
|
Non-Current Financial Instruments |
29,746,881,240 |
28,691,722,880 |
|
|
Tangibles |
38,614,855,709 |
39,615,173,452 |
|
|
Intangibles |
5,448,335,288 |
5,710,692,167 |
|
|
Other Non-Current Assets |
1,736,991,504 |
1,834,191,504 |
|
|
Total Liabilities |
27,283,517,771 |
26,764,509,663 |
|
|
Current Liabilities |
9,686,458,391 |
6,189,534,234 |
|
|
Trade Payables & Other
Payables |
5,422,190,461 |
5,001,210,423 |
|
|
Deferred Income Tax Credit |
88,199 |
4,826,505 |
|
|
Current Portion of Long-Term
Debts |
3,007,600,000 |
103,800,000 |
|
|
Other Current Liabilities |
1,256,579,731 |
1,079,697,306 |
|
|
Non-Current Liabilities |
17,597,059,380 |
20,574,975,429 |
|
|
Provision for Severance &
Retirement |
67,666,809 |
139,306,946 |
|
|
Long-Term Borrowings |
11,926,600,000 |
14,934,200,000 |
|
|
Other Non-Current Liabilities |
1,013,068,395 |
1,001,342,039 |
|
|
Deferred Income Tax Credit |
4,589,724,176 |
4,500,126,444 |
|
|
Capital Stock |
6,370,000,000 |
6,370,000,000 |
|
|
Others |
12,900,663,067 |
12,900,663,067 |
|
|
Profit Surplus |
91,310,761,912 |
82,716,154,556 |
|
|
Total Equity |
110,581,424,979 |
101,986,817,623 |
|
|
Liab. & Shareholder’s Equity |
137,864,942,750 |
128,751,327,286 |
|
Balance
Sheet
|
|||
|
Unit : Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Total Assets |
127,241,490,064 |
111,100,902,479 |
96,274,779,649 |
|
Current Assets |
52,900,157,793 |
47,551,001,107 |
48,134,886,121 |
|
-Quick Assets |
42,649,009,436 |
35,852,788,883 |
39,001,154,700 |
|
-Inventories |
10,251,148,357 |
11,698,212,224 |
9,133,731,421 |
|
Fixed Assets |
74,341,332,271 |
63,549,901,372 |
48,139,893,528 |
|
-Investment |
28,691,722,880 |
957,125,000 |
1,347,245,000 |
|
-Tangibles |
38,104,725,720 |
54,478,714,026 |
39,590,102,796 |
|
-Intangibles |
584,940,701 |
666,848,452 |
519,492,066 |
|
-Others |
6,959,942,970 |
7,447,213,894 |
6,683,053,666 |
|
Total Liabilities |
26,414,191,723 |
31,184,057,884 |
19,264,174,173 |
|
Current Liabilities |
6,189,534,234 |
6,792,590,461 |
14,803,482,407 |
|
Fixed Liabilities |
20,224,657,489 |
24,391,467,423 |
4,460,691,766 |
|
Capital Stock |
6,370,000,000 |
6,370,000,000 |
6,250,000,000 |
|
Capital Surplus |
14,413,199,530 |
14,413,199,530 |
14,413,199,530 |
|
Profit Surplus |
81,556,635,274 |
60,646,181,528 |
57,858,842,576 |
|
Capital Adjustment |
-1,512,536,463 |
-1,512,536,463 |
-1,511,436,630 |
|
Total Equity |
100,827,298,341 |
79,916,844,595 |
77,010,605,476 |
|
Liab. & Shareholder’s Equity |
127,241,490,064 |
111,100,902,479 |
96,274,779,649 |
|
Current Liabilities |
6,189,534,234 |
6,792,590,461 |
14,803,482,407 |
|
Trade Payables |
1,580,076,264 |
722,491,284 |
996,523,099 |
|
Account Payables |
3,421,134,159 |
5,045,717,801 |
11,525,371,468 |
|
Withholdings |
1,056,830,402 |
998,496,824 |
860,109,191 |
|
Advance Receipts |
|
|
|
|
Guarantee Deposit Withhold |
19,300,000 |
16,000,000 |
21,000,000 |
|
Accrued Expenses |
3,566,904 |
9,884,552 |
5,946,365 |
|
Accrued Income Tax |
4,826,505 |
|
1,394,532,284 |
|
Current Portion of Long-Term Debts |
103,800,000 |
|
|
|
Fixed Liabilities |
20,224,657,489 |
24,391,467,423 |
4,460,691,766 |
|
Long-Term Borrowings |
14,934,200,000 |
23,038,000,000 |
3,038,000,000 |
|
Provision for Severance & Retirement |
476,021,710 |
535,077,710 |
534,917,140 |
|
Provisions for Refund |
1,001,342,039 |
1,159,926,956 |
1,139,004,943 |
|
Non-Current Portion of Deferred Income Tax Credit |
4,173,693,054 |
|
75,030,368 |
Income
Statement
|
|||
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Sales |
56,857,631,006 |
54,737,275,045 |
|
|
Cost of Sold Goods |
21,681,108,684 |
22,775,476,262 |
|
|
Gross Profit |
35,176,522,322 |
31,961,798,783 |
|
|
Selling & Admin. Expenses |
27,602,040,989 |
28,355,447,000 |
|
|
Operating Income |
7,574,481,333 |
3,606,351,783 |
|
|
Finance Income |
2,881,900,239 |
1,117,137,931 |
|
|
Finance Expenses |
561,576,137 |
880,428,377 |
|
|
Other Income |
25,980,670 |
24,446,486,464 |
|
|
Income Before Taxes |
9,920,786,105 |
28,289,547,801 |
|
|
Income Taxes Expenses |
98,758,936 |
5,285,443,524 |
|
|
Net Income |
9,822,027,169 |
23,004,104,277 |
|
Income
Statement
|
|||
|
Unit : Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Sales |
54,737,275,045 |
53,093,603,005 |
44,629,977,492 |
|
Cost of Sold Goods |
24,285,923,994 |
20,475,368,946 |
14,826,234,630 |
|
Gross Profit |
30,451,351,051 |
32,618,234,059 |
29,803,742,862 |
|
Selling & Admin. Expenses |
28,355,447,000 |
28,320,544,665 |
24,869,698,996 |
|
Operating Income |
2,095,904,051 |
4,297,689,394 |
4,934,043,866 |
|
Non-Operating Income |
25,747,759,042 |
955,785,646 |
2,455,463,490 |
|
Non-Operating Expenses |
1,064,563,024 |
785,695,458 |
129,125,665 |
|
Income Before Taxes |
26,779,100,069 |
4,467,779,582 |
7,260,381,691 |
|
Income Taxes Expenses |
4,953,145,023 |
962,080,830 |
3,051,193,250 |
|
Net Income |
21,825,955,046 |
3,505,698,752 |
4,209,188,441 |
Cash
Flows
|
|||
|
Unit : Korean Won |
As of 12/31/2011 |
As of 12/31/2010 |
As of 12/31/2009 |
|
Operating Activities Cash Flows |
10,469,593,305 |
5,095,758,268 |
|
|
Net Income |
9,822,027,169 |
23,004,104,277 |
|
|
Adjustment |
-898,094,831 |
-17,360,059,848 |
|
|
Interests Paid |
-561,576,137 |
-880,428,377 |
|
|
Interests Received |
2,119,232,370 |
927,628,256 |
|
|
Income Taxes |
-11,995,266 |
-595,486,040 |
|
|
Cash Flows from Investing |
-16,921,964,223 |
6,816,432,590 |
|
|
Cash Flows from Financing |
-1,324,468,400 |
-8,915,501,300 |
|
|
Increase/Decrease in Cash |
-7,776,839,318 |
2,996,689,558 |
|
|
Cash at the Beginning of Year |
16,012,667,983 |
13,015,978,425 |
|
|
Cash at the End of Year |
8,235,828,665 |
16,012,667,983 |
|
|
Cash Flows |
|||
|
Unit : Korean Won |
As of 12/31/2010 |
As of 12/31/2009 |
As of 12/31/2008 |
|
Cash Flows from Operating |
5,095,758,268 |
-8,333,894,203 |
4,450,152,154 |
|
-Net Income |
21,825,955,046 |
3,505,698,752 |
4,209,188,441 |
|
-Exp. without Cash Outflow |
5,042,874,768 |
2,275,574,065 |
2,164,591,667 |
|
-Revenue without Cash Inflows |
-24,623,312,476 |
-15,413,989 |
-731,798,332 |
|
-Changes in Asset/ & Liability |
2,850,240,930 |
-14,099,753,031 |
-1,191,829,622 |
|
Cash Flows from Investing |
6,816,432,590 |
-4,683,096,768 |
-2,425,763,065 |
|
-Cash Inflow from Investing |
63,409,873,704 |
14,141,863,699 |
61,275,124,665 |
|
-Cash Outflows for Investing |
-56,593,441,114 |
-18,824,960,467 |
-63,700,887,730 |
|
Cash Flows from Financing |
-8,915,501,300 |
19,400,540,367 |
1,841,280,400 |
|
-Cash Inflows from Financing |
|
20,000,000,000 |
3,038,000,000 |
|
-Cash Outflows from Financing |
-8,915,501,300 |
-599,459,633 |
-1,196,719,600 |
|
Increase/Decrease in Cash |
2,996,689,558 |
6,383,549,396 |
3,865,669,489 |
|
Cash at the Beginning of Year |
13,015,978,425 |
6,632,429,029 |
2,766,759,540 |
|
Cash at the End of Year |
16,012,667,983 |
13,015,978,425 |
6,632,429,029 |
|
Main Products & Services |
Respiratory, Antibiotics, Anti-Virus,
Dermatology, Pain/Inflammation, Gastrointestinal, Cardiovascular, Metabolism,
Urological, Ant-Histamines Brand Name : NOMA |
|
Detailed Products Spec. |
|
|
Technologies Acquired |
|
|
Suppliers |
|
|
Customers |
|
|
Competitors |
DONGA PHARMACEUTICAL CO.,
LTD.(110111-0017990) 252, YONGDU-DONG, DONGDAEMUN-GU, TEL:+82-2-920-8114 FAX:+82-2-924-2662 HANMI PHARM CO., LTD.(110111-0014409) 893-5, HAJEO-RI, PALTAN-MYEON, HWASEONG-SI,
TEL:+82-31-356-3311 FAX:+82-31-356-5151 GREEN CROSS CORPORATION(110111-0109854) 303, BOJEONG-DONG, GIHEUNG-GU, YONGIN-SI, TEL:+82-31-260-9300 FAX:+82-31-260-9413 |
|
Affiliates |
|
|
Overseas Office |
|
|
Liaison Office |
|
|
Overseas Branch |
|
|
Joint Venture |
|
|
Subsidiary |
|
|
Corporate Ownership |
|
|
Major Shareholders |
|
|
Cooperative |
|
Not Available.
No.
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.52.68 |
|
|
1 |
Rs.85.12 |
|
Euro |
1 |
Rs.69.38 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.